PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer

Thrombosis Research

Volumn 111, Issue 4-5, 2003, Pages 317-319

  Eroǧlu, Aydan ^a   Çam, Ragip ^b   Yildiz, Züleyha ^b   Akar, Nejat ^b  

^a Numune State Hospital   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Activated protein C resistance; APCR; Deep venous thrombosis; DVT; Factor V; Factor V Leiden; FV; FVL; PCR; Polymerase chain reaction; Prothrombin; PT; STP; Superficial thrombophylebitis; TE; Thromboembolism; Venous thromboembolism; VTE

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 5 LEIDEN; CHLOROFORM; GENOMIC DNA; HISTIDINE; PHENOL; PROTHROMBIN; TAMOXIFEN;

ADULT; AGED; AMINO ACID SUBSTITUTION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC APPROACH ROUTE; DNA EXTRACTION; DNA ISOLATION; FEMALE; HUMAN; LETTER; LUNG EMBOLISM; MUTATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHLEBITIS; VEIN THROMBOSIS; VENOUS BLOOD;

EID: 0345802674     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.09.011     Document Type: Letter

References (23)

1. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H.et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
2. Alhenc-Gelas M., Nicaud V., Gandrille S., van Dreden P., Amiral J., Aubry M.L.et al. The factor V gene A4070 mutation and the risk of venous thrombosis. Thromb. Haemost. 81:1999;193-197.
3. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased in venous thrombosis. Blood. 88:1996;3698-3703.
4. Beauchamp N.J., Daly M.E., Hampton K.K., Cooper P.C., Preston F.E., Peake I.R. High prevalence of a mutation in the factor V gene within the UK population: relationship to activated protein C resistance and familial thrombosis. Br. J. Haematol. 88:1994;219-222.
5. Svensson P.J., Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N. Engl. J. Med. 330:1994;517-522.
6. Akar N., Akar E., Dalgin G., Sozuoz K., Omurlu K., Cin S. Frequency of factor V (1691 G-A) mutation in Turkish population. Thromb. Haemost. 78:1997;1527-1528.
7. Akar N., Akar E., Yilmaz E. Factor V (His1299Arg) in Turkish patients with venous thromboembolism. Am. J. Hematol. 63:2000;102-103.
8. Price D.T., Ridker P.M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann. Intern. Med. 127:1997;895-903.
9. De Stefano V., Chiusolo P., Paciaroni K., Leone G. Epidemiology of factor V Leiden: clinical implications. Semin. Thromb. Hemost. 24:1998;367-379.
10. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gln mutation in Factor V as a pathogenic risk factor for venous thrombosis. Thromb. Haemost. 74:1995;139-148.
11. Manten B., Westendorp R.G., Koster T., Reitsma P.H., Rosendaal F.R. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb. Haemost. 76:1996;510-513.
12. Trousseau A. Phlegmasia alba dolens. Clinique medicale du L'Hotel-Dieu de Paris. 2nd ed. 1865;654-712 Bailliere, Paris.
13. Rickles F.R., Levine M., Edwards R.L. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 11:1992;237-248.
14. Rickles F.R., Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb. Res. 102:2001;215-224.
15. Doll D.C., Yarbro J.W. Vascular toxicity associated with anti-neoplastic agents. Semin. Oncol. 19:1992;580-596.
16. Pritchard K.I.et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J. Clin. Oncol. 14:1996;2731-2737.
17. Nicolson G.L., Custead S.E. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res. 45:1985;331-336.
18. Meier C.R., Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br. J. Pharmacol. 45:1998;608-612.
19. Otterson G.A., Monahan B.P., Harold N., Steinberg S.M., Frame J.N., Kaye F.J. Clinical significance of the FV: Q 506 mutation in unselected oncology patients. Am. J. Med. 101:1996;406-412.
20. Sifontes M.T., Nuss R., Hunger S.P., Wilimas J., Jacobson L.J., Manco-Johnson M.J. The factor V Leiden mutation in children with cancer and thrombosis. Br. J. Haematol. 96:1997;484-489.
21. Haim N., Lanir N., Hoffman R., Haim A., Tsalik M., Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am. J. Med. 110:2001;91-96.
22. Weitz I.C., Israel V.K., Liebman H.A. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 79:1997;2024-2027.
23. Castaman G., Lunghi B., Missiaglia E., Bernardi F., Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Br. J. Haematol. 99:1997;257-261.